Updated results from the positive PACIFIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated a sustained, clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit at five years in patients with unresectable Stage III non-small cell lung cancer (NSCLC) who had not progressed following concurrent chemoradiation therapy (CRT).
[AstraZeneca, Inc. (BusinessWire, Inc.)]
7753456
nan
items
1
apa
0
default
asc
1
163275
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/